A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity

Experimental and Molecular Pathology

Volumn 98, Issue 2, 2015, Pages 178-183

  León Mimila, Paola ^a   Vega Badillo, Joel ^a   Gutiérrez Vidal, Roxana ^a   Villamil Ramírez, Hugo ^a   Villareal Molina, Teresa ^b   Larrieta Carrasco, Elena ^c   López Contreras, Blanca E ^a   Kauffer, Luis R Macías ^a   Maldonado Pintado, Diana G ^d   Méndez Sánchez, Nahúm ^e   Tovar, Armando R ^c   Hernández Pando, Rogelio ^c   Velázquez Cruz, Rafael ^b   Campos Pérez, Francisco ^d   Aguilar Salinas, Carlos A ^c   Canizales Quinteros, Samuel ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INMEGEN   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d Clínica de Obesidad Hospital Rubén Leñero   (Mexico)

^e Fundacion Clinica Medica   (Mexico)

Author keywords

GRS; Liver fat content; NAFLD; NASH; Polymorphisms

Indexed keywords

ALANINE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ADIPONUTRIN, HUMAN; CHOLESTEROL; GCKR PROTEIN, HUMAN; LECTIN; LYPLAL1 PROTEIN, HUMAN; LYSOPHOSPHOLIPASE; MEMBRANE PROTEIN; NCAN PROTEIN, HUMAN; NERVE PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 1; PPP1R3B PROTEIN, HUMAN; PROTEOCHONDROITIN SULFATE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GCKR GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC RISK SCORE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LIPID LIVER LEVEL; LIVER BIOPSY; LIVER HISTOLOGY; LYPLAL1 GENE; MAJOR CLINICAL STUDY; MALE; MEXICAN; MORBID OBESITY; NCAN GENE; NONALCOHOLIC FATTY LIVER; PNPLA3 GENE; PPP1R3B GENE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; CAUCASIAN; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; LIVER; METABOLISM; MEXICO; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; CHOLESTEROL; CHONDROITIN SULFATE PROTEOGLYCANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LECTINS, C-TYPE; LIPASE; LIVER; LYSOPHOSPHOLIPASE; MALE; MEMBRANE PROTEINS; MEXICO; NERVE TISSUE PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PHOSPHATASE 1; TRIGLYCERIDES;

EID: 84924603398     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.01.012     Document Type: Article

References (44)

1. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem. J. 2008, 414:1-18.
2. Alexander D.H., Novembre J., Lange K. Fast model-based estimation of ancestry in unrelated individuals. Genome Res. 2009, 19:1655-1664.
3. Argentou M., Tiniakos D.G., Karanikolas M., et al. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes. Surg. 2009, 19:1313-1323.
4. Bellentani S., Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease. Ann. Hepatol. 2009, 8:S4-S8.
5. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
6. Burke J.E., Dennis E.A. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid Res. 2009, 50:S237-S242.
7. Burke J.E., Dennis E.A. Phospholipase A2 biochemistry. Cardiovasc. Drugs Ther. 2009, 23:49-59.
8. Caballero F., Fernández A., De Lacy A.M., et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J. Hepatol. 2009, 50:789-796.
9. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100.
10. Dwyer A., Doppman J.L., Adams A.J., et al. Influence of glycogen on liver density: computed tomography from a metabolic perspective. J. Comput. Assist. Tomogr. 1983, 7:70-73.
11. Farell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
12. Fesinmeyer M.D., Meigs J.B., North K.E., et al. Genetic variants associated with fasting glucose and insulin concentrations in an ethnically diverse population: results from the Population Architecture using Genomics and Epidemiology (PAGE) study. BMC Med. Genet. 2013, 25:98.
13. Folch J., Lees M., Sloane-Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226:497-509.
14. Gorden A., Yang R., Yerges-Armstrong L.M., et al. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. Hum. Hered. 2013, 75:34-43.
15. Guajardo-Salinas G.E., Hilmy A. Prevalence of nonalcoholic fatty liver disease (NAFLD) and utility of FIBROspect II to detect liver fibrosis in morbidly obese Hispano-American patients undergoing gastric bypass. Obes. Surg. 2010, 20:1647-1653.
16. Guichelaar M.M., Gawrieh S., Olivier M., et al. Interactions of allelic variance of PNPLA3 with non genetic factors in predicting nonalcoholic steatohepatitis and non hepatic complications of severe obesity. Obesity (Silver Spring) 2013, 21:1935-1941.
17. He S., McPhaul C., Li J.Z., et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 2010, 285:6706-6715.
18. Hernaez R., McLean J., Lazo M., et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin. Gastroenterol. Hepatol. 2013, 11:1183-1190.
19. Kelly T., Yang W., Chen C.S., et al. Global burden of obesity in 2005 and projections to 2030. Int. J. Obes. 2008, 32:1431-1437.
20. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
21. Kosoy R., Nassir R., Tian C., et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum. Mutat. 2009, 30:69-78.
22. Kotronen A., Johansson L.E., Johansson L.M., et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52:1056-1060.
23. Larrieta-Carrasco E., León-Mimila P., Villarreal-Molina T., et al. Association of the I148M/PNPLA3 variant with elevated alanine transaminase levels in normal-weight and overweight/obese Mexican children. Gene 2013, 15:185-188.
24. Larrieta-Carrasco E., Acuña-Alonzo V., Velázquez-Cruz R., et al. PNPLA3 I148M polymorphism is associated with elevated alanine transaminase levels in Mexican Indigenous and Mestizo populations. Mol. Biol. Rep. 2014, 10.1007/s11033-014-3341-0.
25. León-Mimila P., Villamil-Ramirez H., Villalobos-Comparan M., et al. Contribution of common genetic variants to obesity and obesity-related traits in Mexican children and adults. PLoS One 2013, 10.1371/journal.pone.0070640.
26. Lin Y.C., Chang P.F., Chang M.H., et al. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am. J. Clin. Nutr. 2014, 99:869-874.
27. López-Velázquez J.A., Silva-Vidal K.V., Ponciano-Rodríguez G., et al. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann. Hepatol. 2014, 13:166-178.
28. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
29. Palmer N.D., Musani S.K., Yerges-Armstrong L.M., et al. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. Hepatology 2013, 58:966-975.
30. Puri P., Baille R.A., Wiest M.M., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
31. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40:1461-1465.
32. Romeo S., Sentinelli F., Dash S., et al. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int. J. Obes. 2010, 34:190-194.
33. Rotman Y., Koh C., Zmuda J.M., et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010, 52:894-903.
34. Schwimmer J.B., Celedon M.A., Lavine J.E., et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009, 136:1585-1592.
35. Sookoian S., Castano G.O., Burgueno A.L., et al. A nonsynonymous gene variant in adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J. Lipid Res. 2009, 50:2111-2116.
36. Speliotes E.K., Butler J.L., Palmer C.D., et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010, 52:904-912.
37. Speliotes E.K., Yerges-Armstrong L.M., Wu J., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011, 10.1371/journal.pgen.1001324.
38. Stepanova M., Hossain N., Afendy A., et al. Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. Obes. Surg. 2010, 20:640-650.
39. The American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33:S62-S69.
40. Valenti L., Al-Serri A., Daly A.K., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1209-1217.
41. Villarreal-Molina M.T., Aguilar-Salinas C.A., Rodriguez-Cruz M., et al. The ATP-binding cassette transporter A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: association with obesity and obesity-related comorbidities. Diabetes 2007, 56:1881-1887.
42. Wagenknecht L.E., Palmer N.D., Bowden D.W., et al. Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study. Liver Int. 2011, 31:412-416.
43. Walker R.W., Sinatra F., Hartiala J., et al. Genetic and clinical markers of elevated liver fat content in overweight and obese Hispanic children. Obesity (Silver Spring) 2013, 21:E790-E797.
44. World Health Organization (WHO) Obesity: preventing and managing the global epidemic. Tech. Rep. Ser. 2000, 894:1-253.